期刊
TRIALS
卷 22, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13063-021-05491-3
关键词
Rifampin-resistant tuberculosis; Rifampicin-resistant tuberculosis; Bedaquiline; Delamanid; Linezolid; Clofazimine; Fluoroquinolone; Pyrazinamide; Treatment shortening; MDR-TB; Non-inferiority; Bayesian adaptive randomization
资金
- National Institute of Allergy and Infectious Diseases at the US National Institutes of Health [K08 AI141740, L30 AI120170, P30 AI060354]
- l Dr. Lynne Reid/Drs. Eleanor and Miles Shore Fellowship at Harvard Medical School
- Burke Global Health Fellowship at the Harvard Global Health Institute
- Harvard University Center for AIDS Research
The treatment of multidrug-resistant and rifampin-resistant tuberculosis remains challenging, with a need for shorter, safer, and more effective regimens. The endTB trial aims to provide better treatment options and explore the efficacy and safety of different treatment regimens.
Background: Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many who do are treated for 18 months or more. A shorter all-oral regimen is currently recommended for only a sub-set of MDR/RR-TB. Its use is only conditionally recommended because of very low-quality evidence underpinning the recommendation. Novel combinations of newer and repurposed drugs bring hope in the fight against MDR/RR-TB, but their use has not been optimized in all-oral, shorter regimens. This has greatly limited their impact on the burden of disease. There is, therefore, dire need for high-quality evidence on the performance of new, shortened, injectable-sparing regimens for MDR-TB which can be adapted to individual patients and different settings. Methods: endTB is a phase III, pragmatic, multi-country, adaptive, randomized, controlled, parallel, open-label clinical trial evaluating the efficacy and safety of shorter treatment regimens containing new drugs for patients with fluoroquinolone-susceptible, rifampin-resistant tuberculosis. Study participants are randomized to either the control arm, based on the current standard of care for MDR/RR-TB, or to one of five 39-week multi-drug regimens containing newly approved and repurposed drugs. Study participation in all arms lasts at least 73 and up to 104 weeks post-randomization. Randomization is response-adapted using interim Bayesian analysis of efficacy endpoints. The primary objective is to assess whether the efficacy of experimental regimens at 73 weeks is non-inferior to that of the control. A sample size of 750 patients across 6 arms affords at least 80% power to detect the non-inferiority of at least 1 (and up to 3) experimental regimens, with a one-sided alpha of 0.025 and a non-inferiority margin of 12%, against the control in both modified intention-to-treat and per protocol populations. Discussion: The lack of a safe and effective regimen that can be used in all patients is a major obstacle to delivering appropriate treatment to all patients with active MDR/RR-TB. Identifying multiple shorter, safe, and effective regimens has the potential to greatly reduce the burden of this deadly disease worldwide.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据